These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12846732)

  • 1. Effects of glucagon-like peptide-1 and feeding on gastric volumes in diabetes mellitus with cardio-vagal dysfunction.
    Delgado-Aros S; Vella A; Camilleri M; Low PA; Burton DD; Thomforde GM; Stephens D
    Neurogastroenterol Motil; 2003 Aug; 15(4):435-43. PubMed ID: 12846732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans.
    Delgado-Aros S; Kim DY; Burton DD; Thomforde GM; Stephens D; Brinkmann BH; Vella A; Camilleri M
    Am J Physiol Gastrointest Liver Physiol; 2002 Mar; 282(3):G424-31. PubMed ID: 11841992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitrergic contribution to gastric relaxation induced by glucagon-like peptide-1 (GLP-1) in healthy adults.
    Andrews CN; Bharucha AE; Camilleri M; Low PA; Seide B; Burton D; Baxter K; Zinsmeister AR
    Am J Physiol Gastrointest Liver Physiol; 2007 May; 292(5):G1359-65. PubMed ID: 17290009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
    Nauck MA; Niedereichholz U; Ettler R; Holst JJ; Orskov C; Ritzel R; Schmiegel WH
    Am J Physiol; 1997 Nov; 273(5):E981-8. PubMed ID: 9374685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
    Willms B; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Nauck MA
    J Clin Endocrinol Metab; 1996 Jan; 81(1):327-32. PubMed ID: 8550773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of glucagon-like peptide-1 and sympathetic stimulation on gastric accommodation in humans.
    Andrews CN; Bharucha AE; Camilleri M; Low PA; Seide BM; Burton DD; Nickander KK; Baxter KL; Zinsmeister AR
    Neurogastroenterol Motil; 2007 Sep; 19(9):716-23. PubMed ID: 17727392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
    Lee A; Patrick P; Wishart J; Horowitz M; Morley JE
    Diabetes Obes Metab; 2002 Sep; 4(5):329-35. PubMed ID: 12190996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.
    Meier JJ; Kemmeries G; Holst JJ; Nauck MA
    Diabetes; 2005 Jul; 54(7):2212-8. PubMed ID: 15983224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans.
    Schirra J; Houck P; Wank U; Arnold R; Göke B; Katschinski M
    Gut; 2000 May; 46(5):622-31. PubMed ID: 10764704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GLP-1 regulates gastroduodenal motility involving cholinergic pathways.
    Schirra J; Nicolaus M; Woerle HJ; Struckmeier C; Katschinski M; Göke B
    Neurogastroenterol Motil; 2009 Jun; 21(6):609-18, e21-2. PubMed ID: 19220754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes.
    Gutniak MK; Svartberg J; Hellström PM; Holst JJ; Adner N; Ahrén B
    J Intern Med; 2001 Jul; 250(1):81-7. PubMed ID: 11454146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow.
    Wettergren A; Wøjdemann M; Holst JJ
    Am J Physiol; 1998 Nov; 275(5):G984-92. PubMed ID: 9815028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat.
    Bucinskaite V; Tolessa T; Pedersen J; Rydqvist B; Zerihun L; Holst JJ; Hellström PM
    Neurogastroenterol Motil; 2009 Sep; 21(9):978-e78. PubMed ID: 19453518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men.
    Näslund E; Gutniak M; Skogar S; Rössner S; Hellström PM
    Am J Clin Nutr; 1998 Sep; 68(3):525-30. PubMed ID: 9734726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance.
    Ritzel R; Schulte M; Pørksen N; Nauck MS; Holst JJ; Juhl C; März W; Schmitz O; Schmiegel WH; Nauck MA
    Diabetes; 2001 Apr; 50(4):776-84. PubMed ID: 11289042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM.
    Dupre J; Behme MT; Hramiak IM; McFarlane P; Williamson MP; Zabel P; McDonald TJ
    Diabetes; 1995 Jun; 44(6):626-30. PubMed ID: 7789625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholecystokinin regulates satiation independently of the abdominal vagal nerve in a pig model of total subdiaphragmatic vagotomy.
    Ripken D; van der Wielen N; van der Meulen J; Schuurman T; Witkamp RF; Hendriks HF; Koopmans SJ
    Physiol Behav; 2015 Feb; 139():167-76. PubMed ID: 25449395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
    Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients.
    Damci T; Yalin S; Balci H; Osar Z; Korugan U; Ozyazar M; Ilkova H
    Diabetes Care; 2004 May; 27(5):1077-80. PubMed ID: 15111524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans.
    Meier JJ; Gethmann A; Götze O; Gallwitz B; Holst JJ; Schmidt WE; Nauck MA
    Diabetologia; 2006 Mar; 49(3):452-8. PubMed ID: 16447057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.